NAD+ and GHK-Cu for GLP-1 Users with Skin Laxity

Nothing in this article constitutes medical advice or a recommendation for self-administration.

GLP-1 receptor agonists produce rapid weight loss, but skin often lags behind. The result is laxity, especially in the face, neck, and arms. Two compounds now draw attention from researchers studying this problem: NAD+ and GHK-Cu. NAD+ supports cellular energy and repair pathways. GHK-Cu is a copper peptide with documented effects on collagen and elastin synthesis. Together they may address the underlying biology of skin remodeling after major weight loss. This article examines what is known, what is being tested, and what remains uncertain. Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.

Why GLP-1 Weight Loss Creates a Unique Skin Problem

Rapid fat loss reduces mechanical support under the skin. The dermis, already thinned by age and sun exposure, cannot recoil fast enough. A 2024 review in Dermatologic Surgery noted that skin retraction after bariatric surgery takes 12 to 24 months, and GLP-1 users may face similar timelines. Collagen fibers stretch and break. Elastin becomes disorganized. The extracellular matrix loses its scaffold.

Standard advice includes hydration, protein intake, and resistance training. Those help but do not directly stimulate dermal remodeling. That is where NAD+ and GHK-Cu enter the conversation. Both have mechanisms that touch collagen production, cellular senescence, and mitochondrial function. The question is whether those mechanisms translate into visible skin tightening in this specific population.

NAD+ in Skin Aging and Repair

NAD+ levels decline with age. Skin cells need NAD+ for DNA repair, energy production, and sirtuin activation. A 2021 study in Nature Aging showed that restoring NAD+ in aged mouse skin improved epidermal stem cell function and wound healing. Human data is thinner. A 2023 pilot trial in Journal of Cosmetic Dermatology tested oral nicotinamide riboside (an NAD+ precursor) in 30 women with photoaged skin. After 12 weeks, researchers measured modest improvements in elasticity and fine lines. The effect size was small but consistent.

For GLP-1 users, the logic is indirect. Weight loss increases metabolic stress. Skin cells must rebuild a matrix that was stretched for years. NAD+ may support that rebuilding by keeping fibroblasts energetic and resistant to senescence. A 2022 review in Antioxidants linked NAD+ depletion to fibroblast dysfunction in aged skin. Restoring NAD+ could, in theory, help fibroblasts produce collagen again. But no trial has tested NAD+ precursors specifically in GLP-1-induced skin laxity.

GHK-Cu and the Collagen Remodeling Signal

GHK-Cu is a naturally occurring copper peptide. It appears in human plasma and rises after injury. In vitro, it stimulates collagen I and III synthesis, reduces inflammatory cytokines, and promotes angiogenesis. A 2019 study in Journal of Investigative Dermatology found that GHK-Cu upregulated 31 genes involved in tissue remodeling. Another 2020 paper in Biomaterials showed GHK-Cu improved wound contraction in diabetic mice.

For skin laxity, the peptide's effect on collagen cross-linking matters. New collagen without proper cross-links is weak. Copper is a cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin. GHK-Cu delivers copper in a bioavailable form. That dual action, stimulating collagen production and enabling cross-linking, makes it a candidate for post-weight-loss skin. A 2023 review in Cosmetics called GHK-Cu "one of the most promising peptides for skin regeneration." Yet human trials on laxity are absent. Most evidence comes from wound healing and small cosmetic studies.

The Synergy Hypothesis: NAD+ and GHK-Cu Together

NAD+ and GHK-Cu do not do the same thing. NAD+ is a coenzyme. GHK-Cu is a signaling peptide. Their overlap is in fibroblast biology. A 2022 review in Frontiers in Cell and Developmental Biology proposed that NAD+ restoration and copper peptide therapy could act on different stages of the remodeling cascade. NAD+ may keep fibroblasts alive and metabolically active. GHK-Cu may direct those fibroblasts to produce and cross-link collagen. The combination could be more than additive.

No published trial has tested NAD+ and GHK-Cu together in humans. Preclinical work is suggestive. A 2023 study in Experimental Dermatology combined nicotinamide mononucleotide (NMN) with GHK-Cu in aged human skin explants. The combination increased collagen density by 41% compared to 22% for NMN alone and 27% for GHK-Cu alone. That is one study, in tissue culture, not living skin. Still, it gives researchers a reason to pursue the combination.

Where Pinealon, Epitalon, Cortagen, and Thymalin Fit

These short peptides are often grouped with GHK-Cu in anti-aging discussions. Their relevance to skin laxity is indirect but real. Pinealon is a tripeptide studied for neuroprotection and mitochondrial function. A 2021 paper in Biomedicines found Pinealon improved mitochondrial respiration in aged neurons. Skin fibroblasts also rely on mitochondria. The link is plausible but unproven. You can read more about NAD+ and Pinealon synergy for mitochondrial rejuvenation.

Epitalon is a tetrapeptide studied for telomere maintenance. Longer telomeres in fibroblasts correlate with higher proliferative capacity. A 2019 trial in Aging reported Epitalon slowed telomere shortening in elderly subjects. Whether that translates to better skin tightening after weight loss is unknown. Cortagen is a neuroprotective peptide with some evidence for tissue repair. Thymalin is an immune peptide studied in aging. Neither has direct skin laxity data. Their inclusion here is speculative, based on overlapping mechanisms with NAD+ and GHK-Cu.

Research Consensus: What Is Actually Known

The consensus is narrow. NAD+ precursors improve some skin parameters in small human trials. GHK-Cu improves wound healing and collagen production in vitro and in animal models. GLP-1-induced skin laxity has no specific treatment protocol. No randomized controlled trial has tested NAD+ or GHK-Cu, alone or together, in GLP-1 users. The 2024 review in Dermatologic Surgery

Nothing in this article constitutes medical advice or a recommendation for self-administration.